Wall Street Zen Upgrades Claritev (NYSE:CTEV) to Hold

Claritev (NYSE:CTEV) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other analysts have also issued reports on the company. Canaccord Genuity Group boosted their target price on Claritev from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Citigroup reiterated a “buy” rating on shares of Claritev in a research note on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Claritev in a report on Wednesday, June 24th. Barclays assumed coverage on Claritev in a research note on Friday, April 24th. They issued an “overweight” rating and a $28.00 price objective on the stock. Finally, Zacks Research downgraded shares of Claritev from a “hold” rating to a “strong sell” rating in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Claritev has a consensus rating of “Hold” and a consensus price target of $34.50.

Claritev Trading Down 1.8%

Shares of NYSE CTEV opened at $32.00 on Friday. The stock has a fifty day simple moving average of $28.88 and a two-hundred day simple moving average of $23.75. Claritev has a 1-year low of $11.50 and a 1-year high of $74.07. The firm has a market cap of $545.60 million, a price-to-earnings ratio of -1.88 and a beta of 0.74.

Hedge Funds Weigh In On Claritev

A number of large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its stake in Claritev by 2.5% in the 1st quarter. Bank of New York Mellon Corp now owns 18,111 shares of the company’s stock worth $296,000 after purchasing an additional 447 shares during the period. State of Wyoming bought a new stake in shares of Claritev during the fourth quarter valued at about $25,000. Ameritas Investment Partners Inc. bought a new stake in shares of Claritev during the third quarter valued at about $42,000. Legal & General Group Plc purchased a new stake in Claritev in the 3rd quarter worth approximately $45,000. Finally, Invesco Ltd. grew its position in shares of Claritev by 4.8% during the 4th quarter. Invesco Ltd. now owns 22,802 shares of the company’s stock valued at $975,000 after purchasing an additional 1,044 shares in the last quarter. 87.15% of the stock is owned by institutional investors.

More Claritev News

Here are the key news stories impacting Claritev this week:

• Positive Sentiment: Better-than-expected quarterly performance: Claritev reported Q2 revenue of approximately $257.5 million, up 6.6% year over year. The company’s net loss narrowed to $59.2 million from $62.6 million, while adjusted EBITDA reached $155.8 million. Reported earnings also surpassed the consensus loss estimate, although published sources show differing EPS figures depending on the accounting presentation. Claritev Corporation Reports Second Quarter 2026 Results Claritev Reports Q2 Loss and Tops Revenue Estimates
• Positive Sentiment: Raised 2026 guidance: Management now expects full-year revenue of $1.0 billion to $1.02 billion and adjusted EBITDA of $610 million to $620 million. The revenue outlook is above the roughly $994.7 million analyst consensus, signaling confidence in continued operating momentum. Claritev Beats Second-Quarter Expectations and Raises Guidance
• Positive Sentiment: Improved cash generation: Operating cash flow increased to $92.7 million from $61.2 million a year earlier, while free cash flow rose to $54.6 million from $36.6 million. The gains provide additional support for the company’s financial flexibility. Claritev Q2 Revenue Rises 6.6 Percent
• Positive Sentiment: Favorable trading sentiment: Investor commentary focused on the earnings beat, higher guidance and increased trading volume. Six reported insider transactions over the past six months were purchases, with no reported sales, though insider activity is not a guarantee of future performance. Claritev Stock Opinions on Q2 Earnings Beat

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.